Hellen Musana

Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial

James Hakim, Cissy Kityo, Anne Hoppé et al. · The Lancet Infectious Diseases · 2017 · 41 citations · Full text

Pharmacy, Infectious Disease Control, Pharmacotherapy +17

High Rate of HIV Resuppression After Viral Failure on First-line Antiretroviral Therapy in the Absence of Switch to Second-line Therapy

Ravindra K. Gupta, Ruth Goodall, Michael Rañopa et al. · Clinical Infectious Diseases · 2013 · 38 citations · Full text

Pharmacy, Pharmacotherapy, Hiv Control +16

Peripheral neuropathy in HIV patients in sub-Saharan Africa failing first-line therapy and the response to second-line ART in the EARNEST trial

Alejandro Arenas‐Pinto, Godfrey Musoro, Hellen Musana et al. · Journal of NeuroVirology · 2015 · 30 citations

Medicine, Neurology, Pharmacotherapy +14

Lopinavir/Ritonavir Monotherapy after 24 Weeks of Second-Line Antiretroviral Therapy in Africa: A Randomized Controlled Trial (Sara)

Charles F. Gilks, A Sarah Walker, David Dunn et al. · Antiviral Therapy · 2012 · 18 citations

Medicine, Pharmacology, Pharmacotherapy +17

Predictors of failure on second-line antiretroviral therapy with protease inhibitor mutations in Uganda

Hellen Musana, Jude Thaddeus Ssensamba, Mary Nakafeero et al. · AIDS Research and Therapy · 2021 · 17 citations · Full text

Public Health, Biostatistics, Infectious Diseases +12